Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-5745 add-on therapy to TNF inhibitor and methotrexate in moderate to severe rheumatoid arthritis
2016-000897-39Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing GS-5745 add-on with Placebo add-on (2 arms). Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Started Oct 2016; status: completed.
02
Drugs
andecaliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2016-000897-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000897-39.